Galenica AG
SIX:GALE
Intrinsic Value
Galenica AG engages as a health care provider in Switzerland. [ Read More ]
The intrinsic value of one GALE stock under the Base Case scenario is 92.53 CHF. Compared to the current market price of 71.45 CHF, Galenica AG is Undervalued by 23%.
Valuation Backtest
Galenica AG
Run backtest to discover the historical profit from buying and selling GALE stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Galenica AG
Current Assets | 1B |
Cash & Short-Term Investments | 116.2m |
Receivables | 518.3m |
Other Current Assets | 399.1m |
Non-Current Assets | 2B |
Long-Term Investments | 364.2m |
PP&E | 489.3m |
Intangibles | 1.1B |
Other Non-Current Assets | 25.4m |
Current Liabilities | 772.3m |
Accounts Payable | 417.4m |
Accrued Liabilities | 195.6m |
Other Current Liabilities | 159.2m |
Non-Current Liabilities | 747.3m |
Long-Term Debt | 654.1m |
Other Non-Current Liabilities | 93.1m |
Earnings Waterfall
Galenica AG
Revenue
|
3.7B
CHF
|
Cost of Revenue
|
-2.7B
CHF
|
Gross Profit
|
1B
CHF
|
Operating Expenses
|
-850m
CHF
|
Operating Income
|
191.6m
CHF
|
Other Expenses
|
93.7m
CHF
|
Net Income
|
285.4m
CHF
|
Free Cash Flow Analysis
Galenica AG
GALE Profitability Score
Profitability Due Diligence
Galenica AG's profitability score is 52/100. The higher the profitability score, the more profitable the company is.
Score
Galenica AG's profitability score is 52/100. The higher the profitability score, the more profitable the company is.
GALE Solvency Score
Solvency Due Diligence
Galenica AG's solvency score is 68/100. The higher the solvency score, the more solvent the company is.
Score
Galenica AG's solvency score is 68/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
GALE Price Targets Summary
Galenica AG
According to Wall Street analysts, the average 1-year price target for GALE is 78.03 CHF with a low forecast of 71.71 CHF and a high forecast of 85.05 CHF.
Shareholder Return
GALE Price
Galenica AG
Average Annual Return | 13.62% |
Standard Deviation of Annual Returns | 10.47% |
Max Drawdown | -19% |
Market Capitalization | 3.6B CHF |
Shares Outstanding | 49 816 260 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Galenica AG engages as a health care provider in Switzerland. The company is headquartered in Bern, Bern and currently employs 5,533 full-time employees. The company went IPO on 2017-04-07. The firm's business i divided into three business sectors: Retail, Products & Brands, and Services. The firm manages a locally established pharmacies network in Switzerland. The company develops and distributes its own product portfolio, as well as cooperates with a range of business partners, such as Pierre Fabre, Ales Groupe and Vitor Consumer Health for marketing and distribution of such brands as Perskindol, Triofan, A-Derma, Lierac, Phyto, Anti-Brumm and Algifor. Galenica Sante's Services business sector is responsible for management of such logistics sector companies as Galexis, Unione Farmaceutica Distribuzione, Alloga and Medifilm.
Contact
IPO
Employees
Officers
The intrinsic value of one GALE stock under the Base Case scenario is 92.53 CHF.
Compared to the current market price of 71.45 CHF, Galenica AG is Undervalued by 23%.